CardioPulmonary Vascular Biology COBRE

心肺血管生物学 COBRE

• 批准号: 10630735
• 负责人: Gaurav Choudhary
• 金额: $ 91.35万
• 依托单位: OCEAN STATE RESEARCH INSTITUTE, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-06-01 至 2028-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10630735
• 关键词: 2019-nCoV; Advisory Committees; Affect; Area; Award; Biology; Blood Vessels; COVID-19 pandemic; Cardiopulmonary; Cardiovascular Diseases; Cardiovascular system; Cause of Death; Cell Separation; Centers of Research Excellence; Collaborations; Communities; Coronary Arteriosclerosis; Data; Development; Discipline; Disease; Educational workshop; Feedback; Fostering; Funding; Goals; Growth; Home; Human; Infection; Infrastructure; Institution; Investigation; Learning; Legal patent; Lung; Lung diseases; Manuscripts; Mission; Mitochondria; Morbidity - disease rate; Organ; Pathogenesis; Phase; Pilot Projects; Prevention; Productivity; Prognosis; Publishing; Research; Research Personnel; Research Project Grants; Resources; Respiratory Disease; Rhode Island; Scientist; Services; Structure; Vascular Diseases; Virus; Vision; career; catalyst; combat; comorbidity; effective therapy; in vivo imaging; mortality; prevent; programs; pulmonary vascular disorder; respiratory

The vision of the CardioPulmonary Vascular Biology (CPVB) COBRE program is to develop effective approaches to prevent and treat vascular diseases affecting the pulmonary and cardiovascular systems through better understanding of disease mechanisms. This will be accomplished by serving as an interdisciplinary center which promotes collaborative research and provides excellent technical support and resources to investigators. The overall mission of the CPVB COBRE program has been to build the human and technical infrastructure and services that serve as catalysts to increase CPVB research in the state. Cardiovascular and pulmonary diseases are among the leading causes of morbidity and mortality in the US and in the world. Coronary artery disease (CAD) is the leading cause of morbidity and mortality. Respiratory diseases are the 3rd and 4th leading causes of death and are frequently complicated by pulmonary vasculopathy and cardiovascular co-morbidities that markedly worsen prognosis. We have learned that infection with SARS-CoV-2 virus damages multiple organs, with cardiovascular, respiratory, and vascular complications. Thus, there is an important need to understand the pathogenesis of cardiopulmonary vascular diseases in order to develop more effective treatments and prevention. The overall goal of the CPVB COBRE program is to facilitate high impact vascular biology research. The CPVB COBRE program provides infrastructure with administrative, pilot project, and two technical cores, thus providing opportunities to expand areas of investigation, experimental and technical approaches, and scientific collaborations. The specific aims of Phase III CPVB COBRE are to: i) award high-impact research projects in the area of cardiopulmonary vascular biology; ii) provide effective and high-quality services in cell isolation and ex vivo organ function (CIOF), mitochondrial function, and in vivo imaging (MF-II); iii) collaborate with IDeA programs in Rhode Island (RI) and other states to foster scientific networks by providing programming, funding, technical services, and resources to enhance research productivity; and iv) maintain a robust line of investigation in vascular biology that meets the needs of the scientific community and furthers research in prevention and treatment of cardiopulmonary vascular diseases. Continuation of the CPVB COBRE into Phase III will sustain the administrative structure for seminars and workshop planning, engagement, and professional development support of investigators, and expertise in cell isolation and ex vivo organ function, mitochondrial function, and in vivo imaging. We will expand and enrich the vascular biology research community by promoting new collaborations and engaging scientists new to the field from a variety of disciplines. At the end of Phase III, we expect to transition to a sustainable CPVB Center serving as a home to the CVPB research community with high quality core services, significant institutional support, and commitment to continue the development of effective approaches to combat or resolve cardiopulmonary vascular diseases.

心肺血管生物学（CPVB）毛cor计划的愿景是开发有效的方法 预防和治疗影响肺和心血管系统的血管疾病通过更好 了解疾病机制。这将通过担任跨学科中心来实现 促进协作研究，并为研究人员提供出色的技术支持和资源。这 CPVB COBRE计划的总体使命是建立人类和技术基础设施和 作为增加该州CPVB研究的催化剂的服务。心血管和肺部疾病 是美国和世界上发病和死亡率的主要原因之一。冠状动脉疾病 （CAD）是发病率和死亡率的主要原因。呼吸道疾病是第三和第四主要原因 死亡，经常因肺血管病和心血管合并症而复杂 明显恶化的预后。我们了解到，SARS-COV-2病毒感染损害了多个器官， 心血管，呼吸和血管并发症。因此，有重要的需要了解 心肺血管疾病的发病机理，以开发更有效的治疗方法 预防。 CPVB COBRE计划的总体目标是促进高影响力血管生物学研究。 CPVB COBRE计划为基础架构提供了行政，试点项目和两个技术核心， 因此提供了扩大调查领域，实验和技术方法以及 科学合作。第三阶段CPVB COBRE的具体目的是：i）授予高影响力的研究 心肺血管生物学领域的项目； ii）在细胞中提供有效且高质量的服务 分离和离体器官功能（CIOF），线粒体功能和体内成像（MF-II）； iii）合作 在罗德岛（RI）和其他州的想法计划，通过提供编程，以促进科学网络， 资金，技术服务和资源以提高研究生产力； iv）保持一条强大的线路 血管生物学调查，满足科学界的需求，并进一步研究 心肺血管疾病的预防和治疗。将CPVB毛绒延续到相位 III将维持研讨会和研讨会计划，参与度和专业的行政结构 研究人员的开发支持以及细胞隔离和离体器官功能的专业知识，线粒体 功能和体内成像。我们将通过促进而扩展和丰富血管生物学研究界 新的合作和从各个学科中吸引了该领域的科学家。在第三阶段结束时， 我们希望过渡到可持续的CPVB中心，该中心是CVPB研究社区的住所 高质量的核心服务，大量的机构支持以及继续发展的承诺 战斗或解决心肺血管疾病的有效方法。